Meeting Banner
Abstract #1356

Exploring metabolite profiling of patients with secondary progressive multiple sclerosis

Anita Monteverdi1, Bhavana Shantilal Solanky2, Floriana De Angelis2, Domenico Plantone2, Jonathan Stutters2, Nevin John2, Letizia Casiraghi1,3, Ian Marshall4, Sue Pavitt5, Gavin Giovannoni6, Christopher Weir7, Nigel Stallard8, Clive Hawkins9, Basil Sharrack10, Siddharthan Chandran4, Jeremy Chataway2, and Claudia Angela Gandini Wheeler-Kingshott1,2,11

1Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy, 2Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom, 3Brain Connectivity Center, C.Mondino National Neurological Institute, Pavia, Italy, 4Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom, 5Dental Translational and Clinical Research Unit, School of Dentistry, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, 6Department of Neurology, Barts and the London NHS Trust, London, United Kingdom, 7Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, 8Division of Health Sciences, University of Warwick, Coventry, United Kingdom, 9Institute for Science and Technology in Medicine, Keele University, Keele, United Kingdom, 10Academic Department of Neuroscience, Royal Hallamshire Hospital, Sheffield, United Kingdom, 11Brain MRI 3T Research Centre, C. Mondino National Neurological Institute, Pavia, Italy

Proton magnetic resonance spectroscopic imaging (MRSI) quantifies brain metabolism in vivo and has the potential of uncovering the mechanism of action of therapeutic drugs. In this study, we assessed the baseline metabolic profile of 161 patients with secondary progressive multiple sclerosis (SPMS) against a control population by applying a short TE PRESS MRSI protocol at 3T. Based on the results the SPMS population could be divided into different groups (normal/biochemically abnormal) suggesting biochemical heterogeneity within SPMS patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here